CancerDrs

Ovarian Cancer clinical trials in South Dakota

17 actively recruiting ovarian cancer trials at 6 sites across South Dakota.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Phase 3 Recruiting Academic/Other

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…

Sponsor: NRG Oncology
NCT ID: NCT05879926
Sites in South Dakota:
  • Avera Cancer Institute-Aberdeen — Aberdeen, South Dakota
  • Avera Cancer Institute - Mitchell — Mitchell, South Dakota
  • Avera Cancer Institute at Pierre — Pierre, South Dakota
  • Rapid City Regional Hospital — Rapid City, South Dakota
  • Sanford Cancer Center Oncology Clinic — Sioux Falls, South Dakota
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a poly…

Sponsor: NRG Oncology
NCT ID: NCT06580314
Sites in South Dakota:
  • Avera Cancer Institute-Aberdeen — Aberdeen, South Dakota
  • Avera Cancer Institute - Mitchell — Mitchell, South Dakota
  • Avera Cancer Institute at Pierre — Pierre, South Dakota
  • Sanford Cancer Center Oncology Clinic — Sioux Falls, South Dakota
  • Avera Cancer Institute — Sioux Falls, South Dakota
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it dev…

Sponsor: Children's Oncology Group
NCT ID: NCT03067181
Sites in South Dakota:
  • Sanford USD Medical Center - Sioux Falls — Sioux Falls, South Dakota
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer

This phase III trial compares the effect of giving triptorelin vs no triptorelin in preventing ovarian damage in adolescents and young adults (AYAs) with cancer receiving chemotherapy with alkylating agents. Alkylating agents are part of s…

Sponsor: Children's Oncology Group
NCT ID: NCT06513962
Sites in South Dakota:
  • Sanford USD Medical Center - Sioux Falls — Sioux Falls, South Dakota
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

The purpose of this study is to evaluate INCB123667 versus investigator's choice of chemotherapy in participants with platinum-resistant ovarian cancer with cyclin E1 overexpression.

Sponsor: Incyte Corporation
NCT ID: NCT07214779
Sites in South Dakota:
  • Sanford Cancer Center-Sioux Falls — Sioux Falls, South Dakota
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

This clinical trial is designed to evaluate the efficacy and safety of T-DXd in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy, in participants with human epidermal growth factor 2 (HER2)-expr…

Sponsor: Daiichi Sankyo
NCT ID: NCT06819007
Sites in South Dakota:
  • Avera Medical Group Gynecologic — Sioux Falls, South Dakota
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression

This is a randomized, Phase 3 trial designed to evaluate the efficacy and safety of azenosertib compared to Investigator's choice of chemotherapy in subjects with platinum-resistant ovarian cancer whose tumors are positive for cyclin E1 pr…

Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
NCT ID: NCT07546500
Sites in South Dakota:
  • Site 0112 — Sioux Falls, South Dakota
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

This is a randomized, adaptive, open label, multicenter trial to evaluate the safety and efficacy of intraperitoneal (IP) IMNN-001 plus chemotherapy compared to chemotherapy alone.

Sponsor: Imunon
NCT ID: NCT06915025
Sites in South Dakota:
  • Sanford Health — Sioux Falls, South Dakota
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in South Dakota:
  • Rapid City Regional Hospital — Rapid City, South Dakota
  • Sanford Cancer Center Oncology Clinic — Sioux Falls, South Dakota
  • Sanford USD Medical Center - Sioux Falls — Sioux Falls, South Dakota
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

This is a multi-part Phase 2 study to evaluate the efficacy and safety of azenosertib (ZN-c3) in subjects with Platinum-Resistant, High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Part 2 of the study will be conduct…

Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
NCT ID: NCT05128825
Sites in South Dakota:
  • Site 0132 - Avera Cancer Institute — Sioux Falls, South Dakota
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

Ovarian cancer is a lethal disease with an estimated 310,000 new cases and 200,000 deaths experienced worldwide in 2020. The purpose of this study is to assess the adverse events and change in disease activity of mirvetuximab soravtansine …

Sponsor: AbbVie
NCT ID: NCT07059845
Sites in South Dakota:
  • Avera Cancer Institute - Sioux Falls /ID# 278627 — Sioux Falls, South Dakota
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer

This is a Phase 2, multicenter, open-label, single-arm study to evaluate the efficacy and safety of sapanisertib and serabelisib (PIKTOR) with paclitaxel in participants with advanced or recurrent endometrial cancer.

Sponsor: Faeth Therapeutics
NCT ID: NCT06463028
Sites in South Dakota:
  • Avera Cancer Institute — Sioux Falls, South Dakota
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out wh…

Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT04389632
Sites in South Dakota:
  • Sanford Cancer Center — Sioux Falls, South Dakota
  • Sanford USD Medical Center — Sioux Falls, South Dakota
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

This is a Phase 1a/1b, dose-escalation/expansion, consecutive-cohort, open-label study to evaluate the safety, tolerability, PK, PD, and preliminary evidence of antitumor activity of PLN-101095 in combination with pembrolizumab (the study …

Sponsor: Pliant Therapeutics, Inc.
NCT ID: NCT06270706
Sites in South Dakota:
  • Avera Medical Group — Sioux Falls, South Dakota
View on ClinicalTrials.gov →
NA Recruiting Academic/Other

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

This clinical trial evaluates how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for individuals with BRCA1 mutations. Bilateral salpingectomy involves…

Sponsor: NRG Oncology
NCT ID: NCT04251052
Sites in South Dakota:
  • Sanford Cancer Center Oncology Clinic — Sioux Falls, South Dakota
  • Sanford USD Medical Center - Sioux Falls — Sioux Falls, South Dakota
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-19